肝疾患診断市場：診断手法別、エンドユーザー別-2025-2030年の世界予測

肝疾患診断市場は、2023年に99億4,000万米ドルと評価され、2024年には110億9,000万米ドルに達すると予測され、CAGR 12.76％で成長し、2030年には230億5,000万米ドルに達すると予測されています。

肝疾患診断市場は、肝炎、肝硬変、肝がんを含む肝疾患を診断するためのツールや検査に焦点を当てています。生化学検査、画像診断技術、分子診断が含まれ、疾患の早期発見、進行のモニタリング、治療効果の評価に不可欠です。このような診断の必要性は、アルコール摂取、肥満、ウイルス感染などの要因によって肝疾患の有病率が増加していることにあります。同市場は、病院、診断ラボ、研究機関などのヘルスケア環境を対象としており、重要なアプリケーションとして、個別化医療と非侵襲的技術に対する需要の高まりを重視しています。

市場に影響を与える主な成長要因には、技術の進歩、肝臓疾患に対する意識の高まり、正確な診断法に対する需要の急増などがあります。ゲノミクスとプロテオミクスの革新は、より正確な診断への道を開き、標的治療の可能性を高めています。最近の動向としては、精度を向上させ、診断プロセスを迅速化するAI主導の診断ツールの開発が浮上しています。さらに、バイオテクノロジー企業とヘルスケアプロバイダーとのコラボレーションにより、新しい診断ソリューションの迅速な開発と導入が促進されています。

イントロダクションの課題には、高度な診断検査の高コスト、熟練した専門家の限られた利用可能性、新技術の導入を遅らせる規制上のハードルなどがあります。製薬会社は、確立された診断法に慣れた臨床コミュニティからの潜在的な抵抗も考慮しなければならないです。成長を最適化するためには、技術革新は費用対効果が高く、精度が高く、導入が容易な診断ツールに焦点を当てるべきです。バイオマーカーとしての肝臓マイクロRNAの調査、イメージング技術の改良、データ解析のための機械学習アプリケーションは、事業拡大のための有望な手段です。

要するに、肝疾患診断市場は、技術の進歩と精密医療へのニーズの高まりによって、大きな成長の可能性を秘めています。コストや規制の課題に対処し、最先端の調査に投資することで、企業は新たな機会を捉え、市場での地位を強化することができます。

市場力学：急速に進化する肝疾患診断市場の主要市場インサイトを公開

肝疾患診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 急性および慢性肝疾患の有病率の増加
  • 政府および非政府の啓発プログラムの発展
  • 低侵襲診断システムへの消費者の傾斜
• 市場抑制要因
  • 診断機器の高コストと熟練した専門家の不足
• 市場機会
  • 診断システムの技術的進歩
  • 経済国におけるヘルスケアアクセスの改善
• 市場の課題
  • 肝臓診断システムの複雑さ

ポーターの5つの力：肝疾患診断市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：肝疾患診断市場における外部からの影響の把握

外部マクロ環境要因は、肝疾患診断市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：肝疾患診断市場における競合情勢の把握

肝疾患診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス：肝疾患診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、肝疾患診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 急性および慢性肝疾患の罹患率の増加
    • 政府および非政府による啓発プログラムの開発
    • 低侵襲診断システムに対する消費者の傾向
  • 抑制要因
    • 診断機器の高コストと熟練した専門家の不足
  • 機会
    • 診断システムにおける技術的進歩
    • 経済におけるヘルスケアアクセスの改善
  • 課題
    • 肝臓診断システムに関連する複雑さ
• 市場セグメンテーション分析
  • 診断技術：肝疾患診断のための画像診断法の改善に向けた継続的な進歩
  • エンドユーザー：強固なヘルスケアインフラの構築に向けた政府の取り組みにより、世界中の病院が拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 肝疾患診断市場：診断技術別

• 生検
• 内視鏡検査
• イメージング
• 臨床検査

第7章 肝疾患診断市場：エンドユーザー別

• 病院
• 研究所

第8章 南北アメリカの肝疾患診断市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の肝疾患診断市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの肝疾患診断市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • E-Scopics、米国で肝臓内視鏡の商業販売を開始、米国に子会社を開設
  • ストーン・ダイアグノスティックス、線維形成性肝疾患検査を提供
  • 予測的健康インテリジェンスが未診断の肝疾患のためのツールを発表

企業一覧

• Abbott Laboratories
• Bayer AG
• Merck & Co., Inc.
• Boston Scientific Corporation
• Randox Laboratories Ltd.
• Fujifilm Holdings Corporation
• Perspectum Ltd.
• Koninklijke Philips N.V.
• Amgen Inc.
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories, Inc.
• Laboratory Corporation of America Holdings
• BioMerieux SA
• Cook Medical Incorporated
• Siemens Healthineers AG
• Horiba, Ltd.
• Becton, Dickinson and Company
• Ri.Mos. Srl
• Hepatiq, Inc.
• Hologic, Inc.
• Argon Medical Devices, Inc.
• Epigenomics AG
• Medtronic PLC
• Thermo Fisher Scientific, Inc.
• Quest Diagnostics Incorporated

LIST OF FIGURES

• FIGURE 1. LIVER DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. LIVER DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. LIVER DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. LIVER DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. LIVER DISEASE DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 23. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 35. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 37. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 72. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 80. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 82. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. LIVER DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 102. LIVER DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Liver Disease Diagnostics Market was valued at USD 9.94 billion in 2023, expected to reach USD 11.09 billion in 2024, and is projected to grow at a CAGR of 12.76%, to USD 23.05 billion by 2030.

The Liver Disease Diagnostics market focuses on tools and tests to diagnose liver diseases, including hepatitis, cirrhosis, and liver cancer. It involves biochemical tests, imaging techniques, and molecular diagnostics, essential for early disease detection, monitoring progression, and assessing treatment efficacy. The necessity of such diagnostics lies in the increasing prevalence of liver diseases driven by factors like alcohol consumption, obesity, and viral infections. The market serves healthcare settings, including hospitals, diagnostic labs, and research institutes, emphasizing personalized medicine and the rising demand for non-invasive techniques as critical applications.

Key growth factors influencing the market include advancements in technology, increasing awareness of liver conditions, and burgeoning demand for accurate diagnostic procedures. Innovations in genomics and proteomics are paving the way for more precise diagnostics, enhancing the potential for targeted therapies. Recent opportunities are emerging in the development of AI-driven diagnostic tools that improve accuracy and speed up the diagnostic process. Additionally, collaborations between biotech firms and healthcare providers are fostering the rapid development and adoption of novel diagnostic solutions.

Challenges include the high cost of advanced diagnostic tests, limited availability of skilled professionals, and regulatory hurdles that can slow down the introduction of new technologies. Pharmaceutical companies must also consider the potential resistance from a clinical community accustomed to established diagnostic methods. To optimize growth, innovation should focus on cost-effective, highly accurate, and easily deployable diagnostic tools. Research into liver microRNA as biomarkers, improved imaging technologies, and machine learning applications for data analysis are promising avenues for business expansion.

In essence, the liver disease diagnostics market holds significant growth potential, driven by technological advancements and an increasing need for precision medicine. By addressing cost and regulatory challenges and investing in cutting-edge research, companies can capture emerging opportunities and strengthen their market position.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Liver Disease Diagnostics Market

The Liver Disease Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in the Prevalence of Acute and Chronic Liver Diseases
  • Development of Government and Non-Government Awareness Programs
  • Consumer Inclination Towards Minimally Invasive Diagnostic Systems
• Market Restraints
  • High Cost of Diagnostic Devices and Lack of Skilled Professionals
• Market Opportunities
  • Technological Advancements in Diagnostic Systems
  • Improving Healthcare Access in Economies
• Market Challenges
  • Complexity Associated with Liver Diagnostic Systems

Porter's Five Forces: A Strategic Tool for Navigating the Liver Disease Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Liver Disease Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Liver Disease Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Liver Disease Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Liver Disease Diagnostics Market

A detailed market share analysis in the Liver Disease Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Liver Disease Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Liver Disease Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Liver Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Bayer AG, Merck & Co., Inc., Boston Scientific Corporation, Randox Laboratories Ltd., Fujifilm Holdings Corporation, Perspectum Ltd., Koninklijke Philips N.V., Amgen Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Laboratory Corporation of America Holdings, BioMerieux SA, Cook Medical Incorporated, Siemens Healthineers AG, Horiba, Ltd., Becton, Dickinson and Company, Ri.Mos. Srl, Hepatiq, Inc., Hologic, Inc., Argon Medical Devices, Inc., Epigenomics AG, Medtronic PLC, Thermo Fisher Scientific, Inc., and Quest Diagnostics Incorporated.

Market Segmentation & Coverage

This research report categorizes the Liver Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Diagnosis Technique, market is studied across Biopsy, Endoscopy, Imaging, and Laboratory Tests.
• Based on End-user, market is studied across Hospitals and Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in the Prevalence of Acute and Chronic Liver Diseases
    • 5.1.1.2. Development of Government and Non-Government Awareness Programs
    • 5.1.1.3. Consumer Inclination Towards Minimally Invasive Diagnostic Systems
  • 5.1.2. Restraints
    • 5.1.2.1. High Cost of Diagnostic Devices and Lack of Skilled Professionals
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological Advancements in Diagnostic Systems
    • 5.1.3.2. Improving Healthcare Access in Economies
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity Associated with Liver Diagnostic Systems
• 5.2. Market Segmentation Analysis
  • 5.2.1. Diagnosis Technique: Ongoing advances to improve imaging modalities for liver disease diagnosis
  • 5.2.2. End-user: Expansion of hospitals across the world supported by government initiatives for developing robust healthcare infrastructure
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Liver Disease Diagnostics Market, by Diagnosis Technique

• 6.1. Introduction
• 6.2. Biopsy
• 6.3. Endoscopy
• 6.4. Imaging
• 6.5. Laboratory Tests

7. Liver Disease Diagnostics Market, by End-user

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Laboratories

8. Americas Liver Disease Diagnostics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Liver Disease Diagnostics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Liver Disease Diagnostics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. E-Scopics Announces Commercial Launch Of Hepatoscope in the Us And Opens its Subsidiary in the US
  • 11.3.2. Stone Diagnostics to Provide Fibronostics Liver Disease Test
  • 11.3.3. Predictive Health Intelligence Launches Tool For Undiagnosed Liver Disease

Companies Mentioned

• 1. Abbott Laboratories
• 2. Bayer AG
• 3. Merck & Co., Inc.
• 4. Boston Scientific Corporation
• 5. Randox Laboratories Ltd.
• 6. Fujifilm Holdings Corporation
• 7. Perspectum Ltd.
• 8. Koninklijke Philips N.V.
• 9. Amgen Inc.
• 10. F. Hoffmann-La Roche Ltd.
• 11. Bio-Rad Laboratories, Inc.
• 12. Laboratory Corporation of America Holdings
• 13. BioMerieux SA
• 14. Cook Medical Incorporated
• 15. Siemens Healthineers AG
• 16. Horiba, Ltd.
• 17. Becton, Dickinson and Company
• 18. Ri.Mos. Srl
• 19. Hepatiq, Inc.
• 20. Hologic, Inc.
• 21. Argon Medical Devices, Inc.
• 22. Epigenomics AG
• 23. Medtronic PLC
• 24. Thermo Fisher Scientific, Inc.
• 25. Quest Diagnostics Incorporated